ShRNA molecules and methods of use thereof
The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.
1. A bifunctional RNA molecule that comprises a single contiguous sequence or multiple distinct sequences that, individually or collectively, encode two or more RNA molecules, comprising:
a first RNA molecule comprises a first double-stranded sequence, which comprises a first guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene; and
a second RNA molecule comprises a second double-stranded sequence, which comprises a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene, wherein the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene, wherein the bifunctional RNA molecule activates cleavage-dependent and cleavage-independent RNA-induced silencing complex for reducing the expression level of the target gene.
2. The bifunctional RNA molecule of claim 1 , wherein the first and second double-stranded sequences reside within a stem portion of separate stem loop structures.
3. The bifunctional RNA molecule of claim 1 , wherein the nucleic acid sequence encoding the two or more RNA molecules is operably connected to a promoter.
4. The bifunctional RNA molecule of claim 3 , wherein the promoter is selected from at least one of a tumor cell specific promoter, a regulatable promoter, or an inducible promoter.
5. The bifunctional RNA molecule of claim 1 , wherein the first RNA molecule and second RNA molecule initially reside within a single primary transcript.
6. The bifunctional RNA molecule of claim 1 , wherein the bifunctional RNA molecule further comprises a third RNA molecule and a fourth RNA molecule which both comprise double stranded sequences within a stem portion of separate stem loop structures.
7. The bifunctional RNA molecule of claim 6 , wherein the first and second RNA molecules comprise a guide strand sequence that is at least partially complementary to a portion of an mRNA transcript encoded by a first target gene, whereas the third and fourth RNA molecules comprise a guide strand sequence that is at least partially complementary to a portion of an mRNA transcript encoded by a second target gene.
8. The bifunctional RNA molecule of claim 2 , wherein each stem loop structure comprises about 40 to 100 nucleotides, wherein the stem portion thereof comprises about 19-45 nucleotides and a loop portion thereof comprises about 4-25 nucleotides.
9. The bifunctional RNA molecule of claim 8 , wherein each stem loop structure comprises about 50 to 75 nucleotides, the stem portion thereof comprises about 20-30 nucleotides, and the loop portion thereof comprises about 6-15 nucleotides.
10. The bifunctional RNA molecule of claim 1 , wherein (a) the first and second double stranded sequence each reside within a stem portion of separate stem loop structures and (b) each stem portion comprises a nucleic acid sequence that is substantially similar to a sequence of a naturally occurring miRNA molecule.
11. The bifunctional RNA molecule of claim 10 , wherein the naturally occurring miRNA molecule is miR-30.